TITRATED EARLY-STAGE CLINICAL STUDIES COULD "BE CONSIDERED"
TITRATED EARLY-STAGE CLINICAL STUDIES COULD "BE CONSIDERED" as the type of study "to guide the rest of development, to convince yourself you have a drug," Office of Drug Evaluation I Director Robert Temple, MD, suggested on June 8 at the Drug Information Association annual meeting in Washington, D.C. A titration design could save time in the full clinicals in the development of drugs for "hypertension, angina, maybe heart failure, probably chronic pulmonary diseases, certainly chronic pain, cholesterol [and] blood sugar," Temple maintained.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth